ÂÜÀòÂÒÂ×

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI) and a Professor of Medicine at Harvard Medical School. He is the Co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center. Dr. Choueiri’s work led to the development of novel experimental therapies for GU malignancies. In a series of New England Journal of Medicine (NEJM) articles on which he was either first or senior author, Dr. Choueiri and colleagues have made seminal observations that have defined and evolved the treatment of metastatic renal cell carcinoma (RCC) and led to the approval of several therapies such as Cabozantinib, Pazopanib, Avelumab+Axitinib, Cabozantinib+Nivolumab, and others, His research also focuses on the epidemiology, diagnosis, and treatment outcomes of GU cancers, especially through having co-established the International Metastatic RCC Database Consortium criteria for RCC risk stratification. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy. He has also contributed to the understanding of the underlying biology and rationale for therapies in rare histological variants of RCC such as papillary and sarcomatoid RCC. Dr. Choueiri has received research funding from the NCI, the Department of Defense (DOD), the American Society of Clinical Oncology (ASCO), and industry partners. He lectures frequently throughout the United States and around the world. He has over 600 PubMed-indexed publications and is the lead investigator of multiple national and international phase I-III clinical trials in GU cancers.